FDA Approves Truqap
On November 16, 2023, the FDA approved capivasertib (Truqap™, AstraZeneca Pharmaceuticals) in combination with fulvestrant (Faslodex®) and a companion diagnostic...
Read MoreOur New Partner: GRASP
Our newest Metastatic Trial Search partner is Guiding Researchers and Advocates to Scientific Partnerships (GRASP). This organization aims to connect patient...
Read MoreOur New Partner: Unite for HER
Our newest Metastatic Trial Search partner is Unite for HER. This organization provides integrative therapies such as nutrition, acupuncture, massage, yoga, and...
Read MoreEuropean Society for Medical Oncology 2023
The 2023 European Society for Medical Oncology (ESMO) meeting was held October 20-24, 2023 in Madrid, Spain. Click the links below to read about MBC research...
Read MoreBiomarker Testing for MBC: What, When, and How?
Biomarkers are genes, molecules, or other features present in a person and/or in a person’s tumor that tell doctors something about a person’s health condition....
Read MoreWhy Are MBC Outcomes Worse for Black Women Than White Women?
Black women and white women are diagnosed with breast cancer at a similar rate. However, Black women are more likely to be diagnosed with an aggressive form of...
Read MoreLeaving a Legacy and Hope: Tissue Donation After Death
As highlighted at the Metastatic Breast Cancer Research Conference 2023, people with MBC can provide hope for other people with MBC by donating their tissue to...
Read MoreMetastatic Trial Search Tutorial Videos: Now Available!
We are excited to announce that Metastatic Trial Search now includes a series of 10 brand-new tutorial videos covering the following topics: Introduction...
Read MoreMetastatic Breast Cancer Research Conference 2023
The Metastatic Breast Cancer Research Conference was held August 30 – September 1, 2023 in Park City, Utah. Click the links below to learn what was...
Read MoreSEARCH OUR SITE
for past articles or specific information.